'Intelligent medicine' erases side effects

Scientists at Aarhus University, Denmark in collaboration with the biotech company Cytoguide now publish a key to use glucocorticoid steroids in a kind of intelligent medicine that specifically hits the relevant cells. Data are based on rodent studies but if this principle is translated to humans it may greatly improve todays hazardous treatment with this type of potent steroids.

This is the main perspective in the research now published in the recognized research journal Molecular Therapy in the .

Synthetic glucocorticoid steroid are used in many acute and including many such as . This is the most potent anti-inflammatory medicine, but its use is hampered by serious side effects such as osteoporosis, loss in muscle mass, diabetes and immunosuppression.

The new data from the scientists now show that they can target the drugs directly to he 'macrophage' . These cells play a main role in inflammation and their damaging effect on the surrounding tissues is strongly dampened by the glucocorticoid steroids.

The new technology is based on the coupling of the steroids to an antibody that specifically binds to a receptor exclusively expressed on the surface of macrophages. The receptors normally take up haemoglobin but they are also able to engulf drug-conjugates binding to the receptors. In the cells, the active steroid is released and it can now execute it effect (gene regulation).

In this way the drug only works in the relevant cells and much less is needed to obtain full efficacy.

'Our project may initially have relevance for inflammation disease and our focus is now on the that affects many persons with fatty liver due to obesity or alcohol abuses' Soren K. Moestrup from Aarhus University says.

'But this technology may also be applied on completely different types of diseases such as cancer' he continues.

If the scientists get financing and collaboration with the large pharma industry in place they expect to have the first conjugate medicine on the market in about 6 years.

More information: "Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone". Molecular Therapy.

add to favorites email to friend print save as pdf

Related Stories

Designing safer glucocorticoid drugs

Dec 01, 2010

Glucocorticoid drugs are used widely to treat numerous conditions, including rheumatoid arthritis, allergic reactions, asthma, and some forms of cancer, and transplant recipients.

Recommended for you

Gamers helping in Ebola research

17 hours ago

Months before the recent Ebola outbreak erupted in Western Africa, killing more than a thousand people, scientists at the University of Washington's Institute for Protein Design were looking for a way to stop the deadly virus.

Carcinogenic role of a protein in liver decoded

19 hours ago

The human protein EGFR controls cell growth. It has mutated in case of many cancer cells or exists in excessive numbers. For this reason it serves as a point of attack for target-oriented therapies. A study ...

A new way to diagnose malaria, using magnetic fields

Aug 31, 2014

Over the past several decades, malaria diagnosis has changed very little. After taking a blood sample from a patient, a technician smears the blood across a glass slide, stains it with a special dye, and ...

User comments